EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic liver cell transplantation to treat murine PKU

Melanie Willimann, Hiu Man Grisch-Chan, Nicole Rimann, Tanja Rothgangl, Martina Hruzova, Gerald Schwank iD, Beat Thöny iD

Journal of Inherited Metabolic Disease · 2024

DOI: 10.1002/jimd.12802 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, 2024. Verfasst von Melanie Willimann und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Metabolism and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Phenylketonurias, Hepatocytes, Disease Models, Animal, Liver. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For gene therapy of the liver, in vivo applications based on adeno‐associated virus are the most advanced vectors despite limitations, including low efficacy and episomal loss, potential integration and safety issues, and high production costs. Alternative vectors and/or delivery routes are of high interest. The regenerative ability of the liver bears the potential for ex vivo therapy using liver cell transplantation for disease correction if provided with a selective advantage to expand and replace the existing cell mass. Here we present such treatment of a mouse model of human phenylketonuria (PKU). Primary hepatocytes from wild‐type mice were gene modified in vitro (with a lentiviral vector) that carries a gene editing system (CRISPR) to inhibit Cypor . Cypor inactivation confers paracetamol (or acetaminophen) resistance to hepatocytes and thus a growth advantage to eliminate the pre‐existing liver cells upon grafting (via the spleen) and exposure to repeated treatment with paracetamol. Grafting Cypor ‐inactivated wild‐type hepatocytes into inbred young adult enu2 (PKU) mice, followed by selective expansion by paracetamol dosing, resulted in replacing up to 5% of cell mass, normalization of blood phenylalanine, and permanent correction of PKU. Hepatocyte transplantation offers thus an armamentarium of novel therapy options for genetic liver defects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhenylketonuriasHepatocytesDisease Models, AnimalLiverGenetic TherapyAnimalsMiceAcetaminophenGene EditingHumans

Stichwörter der Autor:innen

ex vivo gene therapygene editinglentiviral vectorliverphenylketonuria

Substanzen

Acetaminophen

Autor:innen und Institutionen

  • Division of Metabolism and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.
  • University of Zurich, Institute for Pharmacology and Toxicology, Zurich, Switzerland.

ORCID-Profile: Gerald Schwank, Beat Thöny

Förderung

  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Willimann, M., Grisch-Chan, H. M., Rimann, N., Rothgangl, T., Hruzova, M., Schwank, G., & Thöny, B. (2024). Therapeutic liver cell transplantation to treat murine PKU. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.12802

Vancouver

Willimann M, Grisch-Chan HM, Rimann N, Rothgangl T, Hruzova M, Schwank G, et al. Therapeutic liver cell transplantation to treat murine PKU. Journal of Inherited Metabolic Disease. 2024. doi:10.1002/jimd.12802

BibTeX
@article{Willimann2024,
  author = {Willimann, Melanie and Grisch-Chan, Hiu Man and Rimann, Nicole and Rothgangl, Tanja and Hruzova, Martina and Schwank, Gerald and Thöny, Beat},
  title = {Therapeutic liver cell transplantation to treat murine PKU},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2024},
  doi = {10.1002/jimd.12802}
}
Kostenlos starten →